Search Results - "Madden, Katherine G."

Predicting response to checkpoint inhibitors in melanoma beyond PD-L1 and mutational burden by Morrison, Carl, Pabla, Sarabjot, Conroy, Jeffrey M, Nesline, Mary K, Glenn, Sean T, Dressman, Devin, Papanicolau-Sengos, Antonios, Burgher, Blake, Andreas, Jonathan, Giamo, Vincent, Qin, Moachun, Wang, Yirong, Lenzo, Felicia L, Omilian, Angela, Bshara, Wiam, Zibelman, Matthew, Ghatalia, Pooja, Dragnev, Konstantin, Shirai, Keisuke, Madden, Katherine G, Tafe, Laura J, Shah, Neel, Kasuganti, Deepa, de la Cruz-Merino, Luis, Araujo, Isabel, Saenger, Yvonne, Bogardus, Margaret, Villalona-Calero, Miguel, Diaz, Zuanel, Day, Roger, Eisenberg, Marcia, Anderson, Steven M, Puzanov, Igor, Galluzzi, Lorenzo, Gardner, Mark, Ernstoff, Marc S

“…Immune checkpoint inhibitors (ICIs) have changed the clinical management of melanoma. However, not all patients respond, and current biomarkers including PD-L1…”
Get full text

Proliferative potential and resistance to immune checkpoint blockade in lung cancer patients by Pabla, Sarabjot, Conroy, Jeffrey M, Nesline, Mary K, Glenn, Sean T, Papanicolau-Sengos, Antonios, Burgher, Blake, Hagen, Jacob, Giamo, Vincent, Andreas, Jonathan, Lenzo, Felicia L, Yirong, Wang, Dy, Grace K, Yau, Edwin, Early, Amy, Chen, Hongbin, Bshara, Wiam, Madden, Katherine G, Shirai, Keisuke, Dragnev, Konstantin, Tafe, Laura J, Marin, Daniele, Zhu, Jason, Clarke, Jeff, Labriola, Matthew, McCall, Shannon, Zhang, Tian, Zibelman, Matthew, Ghatalia, Pooja, Araujo-Fernandez, Isabel, Singavi, Arun, George, Ben, MacKinnon, Andrew Craig, Thompson, Jonathan, Singh, Rajbir, Jacob, Robin, Dressler, Lynn, Steciuk, Mark, Binns, Oliver, Kasuganti, Deepa, Shah, Neel, Ernstoff, Marc, Odunsi, Kunle, Kurzrock, Razelle, Gardner, Mark, Galluzzi, Lorenzo, Morrison, Carl

“…Resistance to immune checkpoint inhibitors (ICIs) has been linked to local immunosuppression independent of major ICI targets (e.g., PD-1). Clinical experience…”
Get full text

Next generation sequencing of PD-L1 for predicting response to immune checkpoint inhibitors by Conroy, Jeffrey M, Pabla, Sarabjot, Nesline, Mary K, Glenn, Sean T, Papanicolau-Sengos, Antonios, Burgher, Blake, Andreas, Jonathan, Giamo, Vincent, Wang, Yirong, Lenzo, Felicia L, Bshara, Wiam, Khalil, Maya, Dy, Grace K, Madden, Katherine G, Shirai, Keisuke, Dragnev, Konstantin, Tafe, Laura J, Zhu, Jason, Labriola, Matthew, Marin, Daniele, McCall, Shannon J, Clarke, Jeffrey, George, Daniel J, Zhang, Tian, Zibelman, Matthew, Ghatalia, Pooja, Araujo-Fernandez, Isabel, de la Cruz-Merino, Luis, Singavi, Arun, George, Ben, MacKinnon, Alexander C, Thompson, Jonathan, Singh, Rajbir, Jacob, Robin, Kasuganti, Deepa, Shah, Neel, Day, Roger, Galluzzi, Lorenzo, Gardner, Mark, Morrison, Carl

“…PD-L1 immunohistochemistry (IHC) has been traditionally used for predicting clinical responses to immune checkpoint inhibitors (ICIs). However, there are at…”
Get full text

Proliferative potential and response to nivolumab in clear cell renal cell carcinoma patients by Zhang, Tian, Pabla, Sarabjot, Lenzo, Felicia L., Conroy, Jeffrey M., Nesline, Mary K., Glenn, Sean T., Papanicolau-Sengos, Antonios, Burgher, Blake, Giamo, Vincent, Andreas, Jonathan, Wang, Yirong, Bshara, Wiam, Madden, Katherine G., Shirai, Keisuke, Dragnev, Konstantin, Tafe, Laura J., Gupta, Rajan, Zhu, Jason, Labriola, Matthew, McCall, Shannon, George, Daniel J., Ghatalia, Pooja, Dayyani, Farshid, Edwards, Robert, Park, Michelle S, Singh, Rajbir, Jacob, Robin, George, Saby, Xu, Bo, Zibelman, Matthew, Kurzrock, Razelle, Morrison, Carl

“…Biomarkers predicting immunotherapy response in metastatic renal cell cancer (mRCC) are lacking. PD-L1 immunohistochemistry is a complementary diagnostic for…”
Get full text